Chua Terence C, Mittal Anubhav, Arena Jenny, Sheen Amy, Gill Anthony J, Samra Jaswinder S
Department of Gastrointestinal Surgery, Royal North Shore Hospital, St Leonards, NSW, Australia; Discipline of Surgery, University of Sydney, Sydney, NSW, Australia.
Department of Gastrointestinal Surgery, Royal North Shore Hospital, St Leonards, NSW, Australia; Discipline of Surgery, University of Sydney, Sydney, NSW, Australia.
Am J Surg. 2017 Jun;213(6):1072-1076. doi: 10.1016/j.amjsurg.2016.09.049. Epub 2016 Oct 8.
INTRODUCTION: Distal cholangiocarcinoma remains a rare cancer associated with a dismal outcome. There is a lack of effective treatment options and where disease is amendable to resection, surgery affords the best potential for long-term survival. The aim of this study was to examine the survival outcomes and prognostic factors of patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma. METHODS: Between January 2004 to May 2016, patients who had undergone pancreatoduodenectomy with histologically proven distal cholangiocarcinoma were identified. Clinicopathologic data and survival outcomes were reported. RESULTS: Pancreatoduodenectomy alone was performed in 20 patients (71%) and eight patients (29%) required concomitant vascular resection. The major complication rate was 43% (n = 12). Nineteen patients (68%) had node positive disease. Eighteen patients (64%) had R0 resection. The median survival was 36 months (95%CI 9.7 to 63.8) and 5-year survival rate was 24%. Univariate analysis identified ASA (P < 0.001), tumor grade (P = 0.009) and margin status (P = 0.042) as prognostic factors associated with survival. CONCLUSION: Long-term survival may be achieved in selected patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma, especially in patients who achieved an R0 resection.
引言:肝门部胆管癌仍然是一种罕见的癌症,预后较差。缺乏有效的治疗选择,对于可切除的疾病,手术提供了最佳的长期生存潜力。本研究的目的是探讨接受胰十二指肠切除术治疗肝门部胆管癌患者的生存结果和预后因素。 方法:2004年1月至2016年5月期间,确定接受了经组织学证实为肝门部胆管癌的胰十二指肠切除术的患者。报告临床病理数据和生存结果。 结果:20例患者(71%)仅行胰十二指肠切除术,8例患者(29%)需要同时进行血管切除。主要并发症发生率为43%(n = 12)。19例患者(68%)有淋巴结阳性疾病。18例患者(64%)实现了R0切除。中位生存期为36个月(95%CI 9.7至63.8),5年生存率为24%。单因素分析确定美国麻醉医师协会分级(ASA)(P < 0.001)、肿瘤分级(P = 0.009)和切缘状态(P = 0.042)为与生存相关的预后因素。 结论:对于接受胰十二指肠切除术治疗肝门部胆管癌的特定患者,尤其是实现了R0切除的患者,可能实现长期生存。
Zhonghua Wai Ke Za Zhi. 2009-5-1
Gastroenterol Hepatol (N Y). 2024-3
Pathogens. 2023-6-2
World J Surg. 2023-4
Curr Treat Options Gastroenterol. 2021-3
Ann Transl Med. 2020-6
J Zhejiang Univ Sci B. 2020-7